MTHFD1 (methylenetetrahydrofolate dehydrogenase 1) is a trifunctional enzyme that processes dietary folates through three sequential reactions. It plays a central role in one-carbon metabolism ¹¹ One-carbon metabolism: a network of folate-dependent reactions that shuttle single carbon units for DNA synthesis and methylation, feeding into both nucleotide synthesis ²² For DNA repair and cell division — rapidly dividing cells like gut lining and blood cells are especially dependent and the methylation cycle.

The Mechanism

The G1958A variant (rs2236225) causes an arginine-to-glutamine substitution ³³ Arginine-to-glutamine substitution at position 653 of the protein (p.Arg653Gln) at position 653 of the MTHFD1 protein. The A allele produces a less thermostable enzyme that loses activity more readily at body temperature. This reduces the efficiency of folate processing, particularly the 10-formyltetrahydrofolate synthetase activity that is important for purine synthesis. While the enzyme retains normal substrate affinity, its reduced stability diminishes overall metabolic activity.

The Choline Compensation

What makes MTHFD1 especially interesting is its connection to choline. When MTHFD1 activity is reduced, your body compensates by drawing more heavily on choline as an alternative methyl donor ⁴⁴ The betaine pathway: choline is oxidized to betaine, which donates a methyl group directly to homocysteine, bypassing the folate cycle. This increases your dietary choline requirements significantly. Studies have shown that individuals with the AA genotype who consume low-choline diets are more likely to develop signs of choline deficiency, including fatty liver.

The Evidence

A landmark study by Kohlmeier et al.⁵⁵ Kohlmeier et al.
Kohlmeier M et al. PNAS 2005 — genetic variation in folate-mediated one-carbon transfer predicts susceptibility to choline deficiency demonstrated that the A allele is a risk factor for neural tube defects, independent of MTHFR status. A meta-analysis of nine studies⁶⁶ meta-analysis of nine studies
Shen H et al. MTHFD1 polymorphisms and neural tube defect susceptibility, 2014 with 4,302 NTD patients and 4,238 controls confirmed an increased risk of neural tube defects with the AA genotype (OR=2.63). Subsequent research confirmed that this variant increases choline requirements and that adequate choline intake can compensate for the reduced MTHFD1 activity.

Practical Implications

Egg yolks are the richest common dietary source of choline, providing about 150mg per yolk. Liver is even richer. If you carry the A allele, eating 2-3 egg yolks daily provides meaningful choline support. This is one of the most actionable nutrigenomics findings — a simple dietary change (eating more eggs) can compensate for a clear genetic limitation.

Interactions

MTHFD1 interacts with MTHFR (rs1801133, rs1801131) for overall folate pathway efficiency. It also interacts with PEMT (rs7946) — both variants increase choline requirements, and the combined effect can be substantial.

Deep in the MHC class III region on chromosome 6, the gene DDX39B (also known as BAT1) encodes an RNA helicase with a central role in mRNA export, pre-mRNA splicing, and nuclear export of immune transcripts. A 2017 landmark study in Cell established that a regulatory variant at rs2523506 reduces DDX39B protein production, and that this reduction propagates through a chain of molecular events to increase the risk of multiple sclerosis (MS) — the first rigorous demonstration of biological epistasis in humans. The discovery matters not just for MS genetics but as a proof of concept: two common variants in separate genes, each with modest individual effects, combine to produce a dramatically elevated risk that neither alone explains.

The Mechanism

DDX39B is a DEAD-box RNA helicase¹¹ DEAD-box RNA helicase
A family of enzymes that use ATP hydrolysis to unwind RNA secondary structures and remodel RNA-protein complexes, enabling downstream RNA processing steps. One of its critical functions is promoting the inclusion of IL7R exon 6²² IL7R exon 6
Exon 6 of the IL7R gene encodes a transmembrane anchor; when included, IL7R is expressed on the T cell surface as a membrane-bound receptor. When skipped, the resulting mRNA produces a soluble, secreted form that cannot signal properly during pre-mRNA splicing. When exon 6 is properly included, the interleukin-7 receptor (IL7R) anchors to the T cell surface and signals for T cell survival and differentiation. When exon 6 is skipped, the mRNA encodes a soluble IL7R (sIL7R)³³ soluble IL7R (sIL7R)
The secreted form acts as a decoy receptor, sequestering IL-7 away from surface IL7R and dysregulating T cell homeostasis isoform that is secreted rather than membrane-bound, dysregulating IL-7 signaling in ways that predispose to autoimmunity.

The rs2523506 T allele (reported as "A" on the coding/minus strand in the original paper) lies in the 5' untranslated region of DDX39B. This regulatory change reduces the translational efficiency⁴⁴ translational efficiency
How efficiently a cell's ribosomes convert DDX39B mRNA into DDX39B protein; a less efficient 5' UTR means fewer protein molecules are produced from the same amount of mRNA of DDX39B mRNA — cells with the T allele produce less DDX39B protein. With less DDX39B helicase available, the spliceosome is less able to promote IL7R exon 6 inclusion, and exon 6 skipping increases. This cascade — T allele → less DDX39B protein → more exon 6 skipping → more soluble IL7R → impaired IL-7 signaling → dysregulated T cell homeostasis — provides the mechanistic basis for the variant's MS association.

Subsequent research has broadened the picture considerably. A 2023 eLife study showed that DDX39B is also essential for proper splicing of FOXP3, the master transcription factor of regulatory T cells (Tregs). When DDX39B is depleted, FOXP3 introns are retained, FOXP3 protein is lost, and Treg function collapses — providing a second immune tolerance mechanism under DDX39B control. A 2024 mechanistic study confirmed that DDX39B's ATPase activity (not its helicase activity per se) is required for efficient pre-spliceosome assembly at FOXP3 introns, and demonstrated that MS susceptibility genes are disproportionately enriched among genes affected by DDX39B depletion (p = 0.00013). DDX39B thus emerges as a broad guardian of immune gene splicing, with the T allele at rs2523506 chronically reducing this protection.

The Evidence

Galarza-Muñoz et al. 2017⁵⁵ Galarza-Muñoz et al. 2017
Human Epistatic Interaction Controls IL7R Splicing and Increases Multiple Sclerosis Risk. Cell 169(1):72-84 is the primary study. The team conducted genetic association analysis, reporter assays for translational efficiency, and splicing experiments in primary CD4+ T cells and lymphoblastoid cell lines. Key findings: (1) the DDX39B 5' UTR T allele reduces translation in reporter assays, (2) DDX39B depletion causes increased IL7R exon 6 skipping preferentially in the context of the IL7R risk allele (rs6897932 C allele), and (3) carriers of both risk alleles — the DDX39B T allele and the IL7R C allele — show a combined OR of approximately 2.75 for MS, substantially exceeding what either variant contributes alone.

The epistatic architecture is critical to understand. The IL7R rs6897932 C allele reduces exon 6 splicing efficiency intrinsically (the exon splice site is weaker). The DDX39B T allele reduces the level of the helicase that compensates for this weakness. Together, they remove both the intrinsic and compensatory mechanisms for exon 6 inclusion — a synthetic depletion that explains why the combined genotype confers dramatically elevated risk whereas either alone produces more modest effects.

The 2023 FOXP3 finding (Hirano et al. 2023⁶⁶ Hirano et al. 2023
The RNA helicase DDX39B activates FOXP3 RNA splicing to control T regulatory cell fate. eLife 12) extends this model: MS susceptibility genes are substantially enriched among transcripts sensitive to DDX39B levels (empirical p = 0.00013), suggesting the T allele impairs a broad immune-regulatory splicing program rather than a single target.

The variant maps to chromosome 6p21.3, within the MHC class III region — a genomic area with some of the highest density of immune-related genes in the human genome. Its position in this region means it may co-segregate with other MHC haplotype-specific effects, which complicates precise effect-size estimation but is consistent with strong evolutionary selection pressure on this locus.

Practical Implications

No pharmacological intervention exists that specifically compensates for reduced DDX39B expression. The actionable implications for T allele carriers center on early awareness and monitoring for MS and related autoimmune conditions, and on avoiding environmental triggers that compound autoimmune risk.

MS is a complex disease requiring multiple hits — genetic, environmental (low vitamin D, Epstein-Barr virus infection, smoking, obesity, shift work disrupting circadian rhythms), and stochastic. The T allele is common enough (~16% frequency in Europeans) that most carriers will never develop MS. Nevertheless, the combined double-risk genotype at rs2523506 and rs6897932 confers an OR of approximately 2.75, placing double-risk carriers in a higher-surveillance population.

Modifiable risk factors for MS that are well-supported by evidence include: maintaining adequate serum 25(OH)D (≥50 nmol/L; high-dose D supplementation in MS-risk populations has been studied in clinical trials), avoiding smoking (one of the strongest MS environmental risk factors), maintaining a healthy BMI in adolescence and early adulthood, and — given the EBV connection — awareness that EBV seroconversion in adolescence substantially increases MS risk in genetically susceptible individuals.

Interactions

The defining interaction is between rs2523506 (DDX39B) and rs6897932 (IL7R). These two variants act in the same molecular pathway: DDX39B promotes IL7R exon 6 inclusion; the IL7R rs6897932 C allele weakens the exon 6 splice site. When DDX39B levels are low (T allele at rs2523506) and the splice site is already weak (C allele at rs6897932), exon 6 skipping becomes nearly complete, maximizing sIL7R production and MS risk. This is the epistatic pair described in the 2017 Cell paper with combined OR ≈ 2.75.

This compound interaction is the most important clinical finding — the individual SNP results for rs2523506 are substantially amplified when rs6897932 genotype is known. See the compound action in consolidated_actions.yml for the combined recommendation.

DYRK1B¹¹ Dual-specificity tyrosine-phosphorylation-regulated kinase 1B — a serine/threonine kinase that regulates cell cycle exit, quiescence, and differentiation sits at a cellular crossroads: it puts dividing cells to sleep and shepherds them toward differentiated fates. In fat tissue, this means steering precursor cells toward full adipocyte differentiation. The R102C variant tips that balance hard in one direction, flooding carriers with fat-promoting signals they never should have received.

This variant is not a common risk factor — it is a rare, high-penetrance disease mutation. First described in a landmark 2014 New England Journal of Medicine study²² 2014 New England Journal of Medicine study
Keramati et al. A form of the metabolic syndrome associated with mutations in DYRK1B. NEJM, 2014, the R102C substitution was found to co-segregate perfectly with a devastating metabolic syndrome phenotype — dubbed AOMS3 (Abdominal Obesity-Metabolic Syndrome 3; OMIM #615812) — across three unrelated multigenerational families. Every carrier developed the syndrome; every non-carrier did not.

The Mechanism

The R102C mutation swaps arginine for cysteine at position 102, a residue within the kinase-like domain³³ kinase-like domain
The catalytic core of the DYRK1B protein that phosphorylates target proteins that is conserved across vertebrates. At the molecular level, the mutation impairs the HSP90/CDC37 chaperone-assisted folding⁴⁴ impairs the HSP90/CDC37 chaperone-assisted folding
The R102C protein shows enhanced CDC37 co-chaperone binding, indicating conformational instability of the kinase domain of the kinase domain, causing more than half of the mutant protein to accumulate in detergent-insoluble aggregates⁵⁵ detergent-insoluble aggregates
Approximately 50% of mutant DYRK1B vs ~10% of wild-type accumulates in insoluble cytoplasmic fractions within cells. Paradoxically — and critically — the soluble mutant fraction retains and potentiates gain-of-function effects on downstream targets.

The cellular consequence unfolds through two main channels. First, DYRK1B normally inhibits the SHH (Sonic Hedgehog) and Wnt signaling pathways⁶⁶ SHH (Sonic Hedgehog) and Wnt signaling pathways
Two developmental pathways that suppress fat cell differentiation when active. R102C potentiates this inhibition, removing the brake on adipogenesis and causing precursor cells to differentiate into fat cells faster and more completely. Cells expressing R102C show elevated PPARγ, C/EBPα, and C/EBPβ expression⁷⁷ PPARγ, C/EBPα, and C/EBPβ expression
Master transcription factors that drive adipocyte differentiation; elevated levels in patient-derived adipose stem cells carrying R102C — the master drivers of fat cell identity. Second, DYRK1B promotes expression of glucose-6-phosphatase (G6Pase)⁸⁸ glucose-6-phosphatase (G6Pase)
The enzyme that releases glucose from the liver into the bloodstream, a key target for diabetes drugs, the enzyme central to hepatic glucose output; the R102C variant further amplifies G6Pase expression, driving excess glucose release into the bloodstream and compounding insulin resistance.

The Evidence

The original Keramati et al. NEJM 2014⁹⁹ Keramati et al. NEJM 2014
Keramati AR et al. A form of the metabolic syndrome associated with mutations in DYRK1B. N Engl J Med, 2014 study identified the R102C mutation in three large multigenerational Iranian families. The mutation exhibited complete cosegregation¹⁰¹⁰ complete cosegregation
Every family member carrying the mutation had the full metabolic syndrome phenotype; none without it did with the disease phenotype and was absent in 2,000 ethnically-matched Iranian controls, 3,600 Caucasian US controls, and multiple large exome databases. The clinical phenotype was striking: heterozygous carriers developed central obesity, hypertriglyceridemia, low HDL cholesterol, type 2 diabetes, hypertension, and early-onset coronary artery disease — the full constellation of metabolic syndrome — typically before age 40.

A 2021 Orphanet study¹¹¹¹ 2021 Orphanet study
Mendoza-Caamal et al. Two novel variants in DYRK1B causative of AOMS3. Orphanet J Rare Dis, 2021 expanded the AOMS3 spectrum by identifying two further DYRK1B mutations in unrelated families, with the same autosomal dominant inheritance and full penetrance. Strikingly, affected members showed age-dependent progression¹²¹² age-dependent progression
Central obesity beginning in childhood, morbid obesity by the third decade, overt type 2 diabetes before 40, hypertension emerging in the fifth decade: central obesity begins in childhood, morbid obesity and hypertriglyceridemia develop before age 40, and hypertension emerges in the fifth decade. The 2022 adipose stem cell study¹³¹³ 2022 adipose stem cell study
Armanmehr et al. DYRK1B, PPARG, and CEBPB Expression in Adipose-Derived Stem Cells from Patients Carrying DYRK1B R102C. Metab Syndr Relat Disord, 2022 directly compared fat precursor cells from R102C patients versus healthy controls, confirming accelerated adipogenic differentiation at the transcriptional level.

Given the pathogenic classification in ClinVar, autosomal dominant inheritance, and complete penetrance, this variant warrants aggressive metabolic monitoring and intervention in carriers.

Practical Actions

Because DYRK1B R102C causes early-onset central adiposity and metabolic dysregulation through a defined genetic mechanism, carriers benefit from earlier and more intensive monitoring than the general population. Annual fasting lipid panels, glucose, HbA1c, and blood pressure checks from childhood or early adulthood are warranted. Pharmaceutical strategies that reduce hepatic glucose output (metformin) and improve insulin sensitivity (GLP-1 receptor agonists, SGLT-2 inhibitors) address the specific pathways disrupted by this variant. Dietary approaches that limit glycaemic load and saturated fat directly oppose the adipogenic and gluconeogenic overdrive caused by R102C.

Interactions

DYRK1B interacts with PPARγ (PPARG) biology — the R102C mutation drives elevated PPARγ expression, making the transcriptional target of thiazolidinedione drugs highly active. This raises the question of whether pioglitazone or rosiglitazone might paradoxically worsen adipogenesis in carriers. Clinicians managing AOMS3 carriers should be aware that standard insulin sensitizers designed to activate PPARγ may not behave as expected in this context. The interaction between DYRK1B gain-of-function and PPARG rs1801282 (Pro12Ala) genotype has not been studied but could modulate phenotype severity.

Your body uses the amino acid tryptophan three ways: to make serotonin and melatonin (the sleep hormones), to fuel energy metabolism as NAD+, and — when inflammation is present — to produce quinolinic acid, a potent excitotoxin that keeps the brain in a state of heightened arousal. The enzyme HAAO (3-hydroxyanthranilate 3,4-dioxygenase) sits at the critical branch point that decides how much of your tryptophan ends up as quinolinic acid. The rs3816183 Ile37Val variant alters this enzyme's function, skewing the pathway in ways that raise insomnia risk.

The Mechanism

In the kynurenine pathway, most dietary tryptophan (~95%) is metabolized through kynurenine¹¹ through kynurenine
rather than the 1-2% that becomes serotonin. At the HAAO step, 3-hydroxyanthranilic acid (3-HAA) is converted by HAAO into a semialdehyde intermediate that spontaneously cyclizes into quinolinic acid (QUIN)²² quinolinic acid (QUIN)
a potent NMDA receptor agonist with excitotoxic properties. QUIN is then metabolized to NAD+, but this conversion is easily overwhelmed: the neuronal enzyme that degrades QUIN (QPRT) becomes saturated at concentrations around 300 nM, allowing excess QUIN to accumulate and continuously stimulate NMDA receptors.

The Ile37Val substitution (p.Ile37Val) changes a bulky isoleucine to the smaller valine at position 37, near the active site of this iron-dependent dioxygenase. While detailed kinetic studies on this specific variant are limited, population genetics clearly signals functional impact: the T allele (encoding Val37) has been independently identified in two types of studies — as an insomnia risk locus in the landmark 2019 insomnia GWAS, and as a hypospadias risk factor, consistent with altered quinolinic acid synthesis affecting embryonic development pathways.

Critically, inflammation amplifies this genetic susceptibility. Pro-inflammatory cytokines upregulate the upstream enzyme IDO1, dramatically increasing flux through the entire kynurenine pathway. With an already-altered HAAO, more tryptophan is shunted toward quinolinic acid production instead of toward serotonin and its downstream conversion to melatonin.

The Evidence

The primary genetic evidence comes from a massive insomnia GWAS: Jansen et al. (2019) in Nature Genetics³³ Jansen et al. (2019) in Nature Genetics
Genome-wide analysis of insomnia in 1,331,010 individuals identifies new risk loci and functional pathways identified 202 genome-wide significant loci and performed pathway enrichment analysis that highlighted kynurenine pathway genes — HAAO, KYNU, QPRT, and ACMSD — as a convergent insomnia risk cluster. This is mechanistically coherent: all four encode enzymes in the same metabolic branch responsible for determining the kynurenic acid to quinolinic acid ratio.

The metabolic link to sleep quality is directly demonstrated in human data: Cho et al. (2017)⁴⁴ Cho et al. (2017)
Sleep disturbance and kynurenine metabolism in depression. Journal of Psychosomatic Research found that sleep disturbance was significantly associated with a reduced kynurenic acid/quinolinic acid (KynA/QA) ratio — meaning a shift toward neurotoxic quinolinic acid dominance.

The mechanistic pathway from QUIN elevation to disrupted sleep is established in experimental models: Pocivavsek et al. (2018)⁵⁵ Pocivavsek et al. (2018)
Acute kynurenine challenge disrupts sleep-wake architecture in rats demonstrated that elevated kynurenine (which feeds HAAO to produce QUIN) reduced total REM duration, delayed REM onset, and increased wakefulness, with EEG evidence of impaired theta power during REM — a signature of hippocampal arousal. The mechanism is NMDA receptor hyperactivation and antagonism of α7 nicotinic acetylcholine receptors.

Finally, the NAD+ connection provides a second route to intervention: Weiss (2026)⁶⁶ Weiss (2026)
Vitamin B3 ameliorates sleep duration and quality reviewed clinical evidence that nicotinamide riboside (NR) supplementation — which bypasses HAAO to replenish NAD+ — improves sleep efficiency in individuals with insomnia and supports circadian clock gene function (BMAL1, PER2).

Practical Actions

For T-allele carriers, two complementary strategies address the underlying mechanism: (1) reducing inflammation to limit IDO1 induction and the resulting kynurenine flood through HAAO, and (2) supporting NAD+ levels via a pathway that bypasses HAAO entirely. Timing of tryptophan intake also matters — consuming tryptophan-rich foods in the evening rather than splitting intake evenly across the day preferentially supports serotonin/melatonin synthesis while the liver's kynurenine pathway activity is lower.

Interactions

HAAO Ile37Val acts within a broader kynurenine pathway context. The upstream enzyme KMO (kynurenine 3-monooxygenase) and downstream enzyme QPRT both have functional variants that modulate the same neurotoxic/neuroprotective balance. TT carriers may benefit from looking at their KMO and QPRT variants to understand the full picture of their kynurenine pathway function.

The COMT gene (rs4680) interacts with this pathway indirectly: COMT metabolizes catecholamines that modulate hypothalamic arousal, and individuals with both HAAO TT and COMT AA (low dopamine clearance) may experience compounded sleep-onset difficulty via both NMDA hyperactivation and elevated dopaminergic arousal.

ABCG1 (ATP-binding cassette transporter G1¹¹ ATP-binding cassette transporter G1
a membrane-spanning pump that moves cholesterol and phospholipids from the inner leaflet of cell membranes onto maturing HDL particles, completing the second step of reverse cholesterol transport after ABCA1 initiates lipid loading onto nascent HDL) encodes one of the body's principal cholesterol efflux transporters. Located on chromosome 21q22.3, ABCG1 is expressed in macrophages, liver, and many other tissues, where it loads mature HDL particles with surplus cellular cholesterol for transport back to the liver — a central step in preventing foam cell formation and atherosclerotic plaque development.

rs4148102 is an intronic variant in ABCG1 that has no known effect on the protein sequence itself, but its location within an intron has raised the possibility of subtle effects on ABCG1 splicing, expression, or its response to dietary lipid signals. What distinguishes this variant is not its baseline effect on cholesterol but the way it conditions the body's response to high polyunsaturated fatty acid (PUFA) intake — producing a counterintuitive pattern where a seemingly heart-healthy dietary pattern raises LDL-cholesterol in AA homozygotes.

The Mechanism

The biological basis for this gene-diet interaction is not fully characterized at the molecular level. However, ABCG1 transcription is under LXR²² LXR
liver X receptor — a nuclear receptor activated by oxysterols and certain fatty acid derivatives; once activated, LXR drives expression of ABCG1, ABCA1, and other cholesterol homeostasis genes control. Polyunsaturated fatty acids and their metabolites serve as LXR ligands and can modulate its activity. An intronic variant could influence how effectively the ABCG1 gene responds to these dietary lipid signals — for example, by altering a regulatory element that fine-tunes LXR responsiveness.

When ABCG1 function is subtly impaired or mis-regulated, cholesterol efflux from cells to HDL is reduced. Under high-PUFA dietary conditions, which normally promote LDL receptor upregulation and LDL clearance, the AA variant appears to interfere with this adaptive response, resulting in paradoxically elevated LDL and total cholesterol rather than the reduction seen in GG carriers on the same diet.

The Evidence

The primary evidence comes from a study by Abellán et al.³³ study by Abellán et al.
Abellán R et al. Dietary polyunsaturated fatty acids may increase plasma LDL-cholesterol and plasma cholesterol concentrations in carriers of an ABCG1 gene single nucleotide polymorphism: study in two Spanish populations. Atherosclerosis, 2011 examining 1,941 participants across two independent Spanish cohorts (the Hortega study, n=1,178, and the Pizarra study, n=763). In the Hortega population, AA homozygotes consuming high-PUFA diets had LDL-cholesterol of 149.8 ± 37.9 mg/dL compared to 111.4 ± 32.1 mg/dL in G allele carriers (p=0.005). Total cholesterol diverged similarly (242.1 vs 198.0 mg/dL, p=0.003). Pooling both cohorts strengthened the signal: gene-diet interaction p=0.006 for total cholesterol, p=0.003 for LDL-cholesterol.

The A allele is relatively uncommon globally (~14.5%), making AA homozygosity rare (~2% of the population). This limits replication opportunities and explains why no dedicated follow-up trials exist yet. The evidence level is therefore emerging — a well-designed two-cohort study, but not yet replicated in independent populations or mechanistically confirmed in cell-based assays.

Practical Actions

For AA homozygotes, the clinical implication is specific: high-PUFA diets — which most guidelines recommend as beneficial — may actually raise LDL-cholesterol in this genotype. Rather than increasing total PUFA from vegetable oils (sunflower, corn, safflower), focus on pre-formed long-chain omega-3s (EPA and DHA from fatty fish or supplements) and monitor fasting LDL when making significant dietary changes. Saturated fat should still be limited — this is not a signal to increase saturated fat intake. The issue is specifically with high omega-6 PUFA loads from vegetable oils, not with EPA/DHA.

Carriers of one A allele (AG) represent roughly 25% of people. The gene-diet interaction was strongest in AA homozygotes; AG heterozygotes showed intermediate patterns in some analyses, but the effect was not consistent across both study populations. Standard dietary PUFA guidance applies.

Interactions

ABCG1's role in cholesterol efflux depends on the upstream ABCA1 step (rs1044317 is another ABCG1 variant in the cholesterol_lipoproteins category). If both ABCG1 steps in the efflux pathway are impaired — the initial ABCA1-mediated lipid loading onto nascent HDL, and the ABCG1-mediated maturation step — the combined cholesterol efflux deficit could be larger than either variant alone. FADS1 variants (rs174547, rs174537) also interact with this locus biologically: impaired FADS1 conversion of plant omega-3s to EPA/DHA shifts the circulating PUFA ratio toward omega-6, which may amplify the LDL-raising signal seen with rs4148102 AA on high-PUFA diets.

The R3HDML gene on chromosome 20q13 sits immediately adjacent to a well-characterized regulatory landmark: the P2 promoter of HNF4A (| Hepatocyte Nuclear Factor 4-alpha, a transcription factor critical for pancreatic islet development and insulin secretion). rs4810424 falls within an R3HDML intron, but its biological significance comes from being a reliable tag for the HNF4A P2 promoter risk haplotype — a cluster of SNPs (rs4810424, rs1884613, rs1884614, rs2144908) in nearly complete linkage disequilibrium (D' > 0.97, r² > 0.95) that were originally identified in Finnish and Ashkenazi Jewish populations.

The Mechanism

HNF4A is an orphan nuclear receptor | A transcription factor that binds DNA to regulate gene expression; called "orphan" because its natural ligand was originally unknown that controls genes governing glucose-stimulated insulin secretion, gluconeogenesis, and beta-cell maintenance. Critically, while both the P1 and P2 promoters drive HNF4A expression in liver cells, pancreatic islets rely almost exclusively on the P2 promoter. Common variants tagging the P2 haplotype are therefore expected to alter HNF4A expression disproportionately in the tissue most relevant to type 2 diabetes: the insulin-secreting beta cell.

The P2 haplotype risk alleles are associated with reduced HNF4A transcript levels in islets, impairing the transcriptional cascade that drives expression of insulin, glucose transporter-2 (GLUT2), L-pyruvate kinase, and other metabolic coupling genes. The functional consequence is a blunted insulin secretory response to glucose — a mechanism consistent with the OGTT-based associations observed in Japanese and Thai cohorts | Tokunaga et al., Endocrine J, 2008, PMID 18654034; Jongjaroenprasert et al., Acta Diabetol, 2007, PMID 17805472.

The Evidence

The original discovery came from the FUSION study in Finland, where Silander et al.¹¹ Silander et al.
Silander K et al. Genetic variation near the hepatocyte nuclear factor-4 alpha gene predicts susceptibility to type 2 diabetes. Diabetes, 2004 identified the P2 haplotype association with T2D (OR 1.33, 95% CI 1.06-1.65, p = 0.011) in 495 Finnish affected sibling pairs, with independent replication in Ashkenazi Jewish samples.

A large UK replication study Weedon et al.²² Weedon et al.
Weedon MN et al. Common variants of the hepatocyte nuclear factor-4alpha P2 promoter are associated with type 2 diabetes in the UK population. Diabetes, 2004 confirmed the association in 5,256 Caucasians (OR 1.15, 95% CI 1.02-1.33, p = 0.02). The smaller effect size in the UK compared with Ashkenazi populations (OR ~1.7) suggests the causal variant within the haplotype block differs in frequency or is modified by population background.

In the prospective STOP-NIDDM trial³³ STOP-NIDDM trial
Andrulionyte L et al. SNPs of the HNF4alpha gene are associated with the conversion to type 2 diabetes mellitus: the STOP-NIDDM trial. J Mol Med, 2006, female carriers of the C allele at rs4810424 had a 1.7-fold elevated risk of converting from impaired glucose tolerance to diabetes (OR 1.7, 95% CI 1.09-2.66, p = 0.020), while no association was detected in men. A combined Swedish-Finnish cohort Holmkvist et al.⁴⁴ Holmkvist et al.
Holmkvist J et al. Common variants in maturity-onset diabetes of the young genes and future risk of type 2 diabetes. Diabetes, 2008 found rs4810424 predicted future T2D (HR 1.3, 95% CI 1.0-1.6, p = 0.03) across 17,831 participants.

The association is notably population-specific: the risk effect is strongest in Ashkenazi Jewish individuals, moderate in Scandinavians and Finns, and not consistently replicated in UK Caucasians. The C allele is also far more common in East Asian populations (~44% vs ~17% in Europeans), though its T2D association in Asian cohorts is primarily mediated by rs1884614 and rs2144908 rather than rs4810424 itself.

Practical Actions

Carriers of the risk haplotype — particularly CC homozygotes — have a modestly elevated risk of beta-cell secretory insufficiency that is amenable to dietary and monitoring strategies. A diet that reduces the post-meal glucose load (lower glycemic index, reduced refined carbohydrate) directly offsets the beta-cell demand amplified by impaired HNF4A expression in islets. Prospective data from the STOP-NIDDM trial also showed that acarbose — an alpha-glucosidase inhibitor — partially offset the progression to T2D in high-risk individuals with impaired glucose tolerance, consistent with a glucose-spike mechanism.

Interactions

rs4810424 is in high LD with rs2144908 (r² ≈ 0.97), rs1884614, and rs1884613 within a ~15 kb P2 haplotype block. Carrying risk alleles at multiple haplotype members compounds the beta-cell expression deficit but does not add independent risk beyond the haplotype signal. Separately, published data show an interaction between HNF4A rs2144908 and KCNJ11 E23K (rs5219) — carriers of both risk variants show markedly greater impairment of insulin secretion than either alone, consistent with additive disruption of the ATP- sensitive potassium channel pathway that HNF4A transcriptionally regulates.

Every cell in your body faces a constant barrage of oxidative stress from metabolism, environmental toxins, and inflammation. The primary defense is NRF2¹¹ NRF2
Nuclear factor erythroid 2-related factor 2, encoded by the NFE2L2 gene — the master transcription factor controlling over 200 cytoprotective genes including those responsible for glutathione synthesis, phase II detoxification, heme oxygenase-1, and anti-inflammatory pathways, the master transcription factor that acts like an emergency broadcast system for the body's antioxidant defenses. When a cell detects oxidative stress, NRF2 breaks free from its inhibitor KEAP1, enters the nucleus, and switches on a broad battery of protective genes by binding to antioxidant response elements (AREs)²² antioxidant response elements (AREs)
Short DNA sequences (~23 bases) found in the promoters of NRF2-regulated genes. When NRF2 binds to an ARE, it recruits the transcription machinery to activate gene expression in their promoters.

The rs6721961 variant sits directly within an ARE-like motif in the NFE2L2 promoter itself — a location that appears to serve an auto-regulatory role, allowing NRF2 to amplify its own expression in a positive feedback loop. The T allele disrupts this motif, weakening NRF2's ability to drive its own transcription and blunting the entire downstream cascade.

The Mechanism

The rs6721961 SNP is located at approximately position −617 relative to the NFE2L2 transcription start site (also described as −178 in some coordinate systems based on different reference transcripts). It resides within an ARE-like sequence in the NFE2L2 promoter, a region where NRF2 protein can bind to amplify its own transcription through positive feedback.

In luciferase reporter assays³³ luciferase reporter assays
A standard technique where the promoter region of interest is placed upstream of a firefly luciferase gene. The amount of light produced reflects how strongly the promoter drives transcription using human cell lines, Marzec et al. 2007 showed⁴⁴ Marzec et al. 2007 showed
Marzec JM et al. Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury. FASEB J, 2007 that rs6721961 reduces NFE2L2 promoter activity by over 50% compared to the wild-type G allele. The minor A allele (T on the genomic plus strand) disrupts binding at this site, reducing the auto-regulatory amplification of NRF2 expression. Homozygous AA carriers show substantially lower NRF2 mRNA levels compared to CC or CA genotypes in tissue studies.

The functional consequence extends to the entire NRF2-regulated network: lower NRF2 means less induction of NQO1 (quinone reductase), glutamate-cysteine ligase (rate-limiting enzyme for glutathione synthesis), heme oxygenase-1 (HO-1, anti-inflammatory), and the thioredoxin/sulfiredoxin system. Under normal conditions this reduction may be tolerable; under oxidative challenge — infection, toxin exposure, air pollution, smoking — the buffering capacity is meaningfully lower.

The Evidence

Oxidative stress and diabetes: A study of newly diagnosed type 2 diabetes patients in China by Wang X et al. 2015⁵⁵ Wang X et al. 2015
Wang X et al. Association between the NF-E2 Related Factor 2 Gene Polymorphism and Oxidative Stress, Anti-Oxidative Status, and Newly-Diagnosed Type 2 Diabetes Mellitus in a Chinese Population. Int J Mol Sci, 2015 found that individuals with the AA (TT on plus strand) genotype had significantly lower total antioxidant capacity, superoxide dismutase, catalase, and glutathione peroxidase activity, as well as higher malondialdehyde (a marker of lipid peroxidation) and insulin resistance. This genotype was associated with 1.56-fold increased risk of T2DM (OR 1.56, 95% CI 1.11–2.20).

Neurodegeneration: In Parkinson's disease, the T allele showed a counterintuitive protective association⁶⁶ counterintuitive protective association
Paul KC et al. NFE2L2, PPARGC1α, and pesticides and Parkinson's disease risk and progression. Mech Ageing Dev, 2018 — carriers had OR 0.70 (95% CI 0.53–0.94) for PD risk and significantly slower cognitive decline (MMSE β=0.095, p=0.0004). This paradox likely reflects the complexity of NRF2 in the brain (some studies show high NRF2 in degenerating neurons) and the specific cellular context of dopaminergic vulnerability.

Cardiovascular: In a Finnish cohort (n=816), the rare TT genotype was associated with an 8.8-fold increased risk of cerebrovascular disease⁷⁷ 8.8-fold increased risk of cerebrovascular disease
Kunnas et al. 2016: TAMRISK study of 816 Finnish subjects showing NRF2 rs6721961 TT genotype associated with cerebrovascular disease compared to GG.

Hormone metabolism and VTE: NFE2L2 carriers using oral estrogens had dramatically increased risk of venous thromboembolism⁸⁸ dramatically increased risk of venous thromboembolism
Bouligand J et al. Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembolism in postmenopausal women. Clin Pharmacol Ther, 2011 (OR 17.9 versus OR 2.5 in wild-type), likely due to impaired NRF2-dependent hepatic conjugation of estrogen metabolites.

Cancer: The variant allele has been associated with altered NRF2 protein expression in renal cell carcinoma and with hepatocellular carcinoma risk.

Practical Implications

The T allele means your baseline NRF2 expression is reduced, lowering the ceiling for your antioxidant response. This matters most when oxidative load is high: during infections, heavy exercise, air pollution exposure, alcohol consumption, and smoking. The primary intervention strategy is to bypass the reduced NRF2 auto-induction by using dietary and supplemental NRF2 activators that work through the KEAP1 pathway rather than the promoter — these activate NRF2 protein that is already present, circumventing the transcriptional reduction.

Sulforaphane (from broccoli sprouts) is the most potent dietary NRF2 activator, with a concentration required for activation (CD value) of 0.2 μM — roughly 14-fold more potent than curcumin (2.7 μM) and hundreds-fold more potent than EGCG from green tea (>50 μM). Clinical trials have used broccoli sprout extracts delivering approximately 50–200 μmol sulforaphane per dose. For those who cannot or prefer not to rely on food sources, standardized broccoli sprout extract supplements retaining both glucoraphanin and active myrosinase enzyme provide the most reliable delivery.

Interactions

rs6721961 is part of a three-SNP haplotype in the NFE2L2 promoter along with rs35652124 (−214A>G) and rs6706649 (−212G>A). The low-activity haplotype carrying risk alleles at all three positions (referred to as the "GTC" or "AGA" haplotype depending on the coding-strand notation) shows the most severely reduced promoter activity and has been linked to increased disease risk in multiple cohorts. When genotype results are available for all three SNPs, the combined haplotype is more informative than any single variant alone.

NQO1 (rs1800566) is a direct downstream target of NRF2 — reduced NFE2L2 expression leads to less NQO1 induction. In individuals who carry both the NFE2L2 promoter variant and the NQO1 Pro187Ser variant, the combined reduction in NRF2-dependent antioxidant capacity may be substantially greater than either alone.

SOD2 (rs4880) and GPX1 (rs1050450) are also under partial NRF2 regulation. Combined impairment of NRF2 (upstream regulator) with functional variants in these downstream antioxidant enzymes would compound oxidative stress vulnerability across multiple defense layers.

The BCO1 gene (also known as BCMO1) encodes beta-carotene 15,15'-monooxygenase¹¹ beta-carotene 15,15'-monooxygenase
The enzyme that cleaves dietary beta-carotene into two molecules of retinal, which is then reduced to retinol — the form of vitamin A used by the body, the central enzyme in the conversion of plant-based provitamin A into biologically active vitamin A. Most people are familiar with BCO1 through its two well-studied coding variants — rs7501331 (Ala379Val) and rs12934922 (Arg267Ser) — which directly reduce enzyme activity by up to 69% in compound carriers. The rs7834555 variant represents a third, independently acting influence on circulating beta-carotene and retinol levels, identified through genome-wide association analysis of circulating carotenoid concentrations.

The Mechanism

Unlike the coding BCO1 variants that alter the enzyme's amino acid sequence, rs7834555 is an intergenic variant²² intergenic variant
Located between protein-coding genes; does not directly change any protein but can influence gene regulation through effects on enhancers, transcription factor binding sites, or chromatin accessibility located on chromosome 8 at position 81,785,390 (GRCh38). Its mechanistic connection to carotenoid metabolism is not yet characterized at the molecular level. The variant likely acts as a GWAS tag SNP³³ GWAS tag SNP
A marker in linkage disequilibrium with a functional variant nearby, which has not yet been pinpointed; the tag SNP's association reflects the true causal variant's effect, meaning it serves as a detectable signal for a nearby regulatory element that modulates expression or activity of a gene in the broader carotenoid absorption and conversion pathway.

The intestinal absorption and conversion of beta-carotene is a multi-step process involving several proteins beyond BCO1 itself: membrane transporters such as SR-B1 (SCARB1)⁴⁴ SR-B1 (SCARB1)
Scavenger receptor class B type 1 — a lipid transport protein that facilitates uptake of carotenoids and other fat-soluble compounds into enterocytes and CD36⁵⁵ CD36
A fatty acid translocase that also facilitates carotenoid uptake at the intestinal brush border, retinaldehyde reductases, and CRBP chaperone proteins. Genetic variation that influences any of these steps will independently affect circulating carotenoid and retinol levels.

The Evidence

The association of rs7834555 with circulating beta-carotene and retinol levels comes from genome-wide association study data. The broader framework for understanding how genetic variation near BCO1 modulates carotenoid metabolism was established by Ferrucci et al. 2009⁶⁶ Ferrucci et al. 2009
Ferrucci L et al. Common variation in the β-carotene 15,15′-monooxygenase 1 gene affects circulating levels of carotenoids. Am J Hum Genet, 2009, who performed the first GWAS of circulating carotenoids, identifying the BCMO1/BCO1 locus on chromosome 16 as the strongest genetic determinant of plasma beta-carotene levels.

Subsequent work by Lietz et al. 2012⁷⁷ Lietz et al. 2012
Lietz G et al. Single nucleotide polymorphisms upstream from the β-carotene 15,15′-monoxygenase gene influence provitamin A conversion efficiency in female volunteers. J Nutr, 2012 demonstrated that upstream regulatory SNPs near BCO1 (rs6420424, rs11645428, rs6564851) reduced BCMO1 catalytic activity by 48-59% independently of the coding variants, confirming that non-coding variation is a major contributor to the wide interindividual variability in beta-carotene conversion.

Hendrickson et al. 2012⁸⁸ Hendrickson et al. 2012
Hendrickson SJ et al. β-Carotene 15,15′-monooxygenase 1 SNPs in relation to plasma carotenoid and retinol concentrations in women of European descent. Am J Clin Nutr, 2012 showed that a genetic score using multiple BCO1-region SNPs predicted plasma beta-carotene concentrations with a 48% difference across extreme quintiles in 2,344 European women — underscoring that the full genetic picture of carotenoid metabolism requires considering multiple independent signals.

The evidence for rs7834555 specifically as an independent signal should be considered emerging until replicated in peer-reviewed publications with reported effect sizes and p-values.

Practical Implications

If the A allele of rs7834555 is confirmed as reducing beta-carotene conversion efficiency or retinol status, the practical implications follow the same logic as the better-characterized BCO1 coding variants. People who rely heavily on plant-based provitamin A sources — vegans, vegetarians, and those with limited access to animal-source foods — are most affected. Since this variant acts independently of the coding variants at rs7501331 and rs12934922, individuals who carry all three risk alleles would face cumulative impairment of their beta-carotene-to-retinol conversion pathway.

The most direct way to compensate is to include preformed vitamin A⁹⁹ preformed vitamin A
Retinol from animal sources (liver, egg yolks, dairy, fatty fish) or retinyl palmitate/acetate supplements — bypasses BCO1 entirely and does not require conversion in the diet, which bypasses the BCO1 enzyme entirely and provides retinol directly to the body. For those eating a mixed diet with regular animal products, even substantially reduced BCO1 activity is unlikely to produce clinical vitamin A deficiency.

Interactions

The rs7834555 signal is proposed to be independent of the two major BCO1 coding variants: rs7501331 (Ala379Val, on chromosome 16) and rs12934922 (Arg267Ser, also chromosome 16). If confirmed, individuals carrying the A allele at rs7834555 alongside T alleles at rs7501331 and/or rs12934922 would face additive impairment of their beta-carotene conversion capacity — the combined effect exceeding any single variant alone.

The upstream regulatory BCO1 SNPs (rs6564851, rs6420424, rs11645428) on chromosome 16 are separate signals that also independently influence conversion and may interact further. The full genetic architecture of interindividual variation in beta-carotene conversion thus spans both structural (amino acid) and regulatory (expression-level) effects, with rs7834555 proposed as an additional independent determinant from a distinct genomic locus.

Interleukin-4¹¹ Interleukin-4
IL-4 is the master Th2 cytokine secreted by activated CD4+ T cells, mast cells, basophils, and innate lymphoid cells type 2 (ILC2s); it drives naïve T cell polarization toward the Th2 phenotype, instructs B cells to switch antibody class to IgE, and maintains mast cell and eosinophil survival is the central regulator of the allergy-prone immune state. The IL4 gene sits on chromosome 5q31.1, a region long known to harbour susceptibility loci for atopic disease. rs2070874 is a C-to-T substitution 33 bases into the 5'-untranslated region (5'-UTR) of the IL4 transcript — between the transcription start site and the protein-coding start codon. At this position, the variant does not change the IL-4 protein but alters the RNA sequence in a way that influences how efficiently the mRNA is translated and, indirectly, how much IL-4 protein is ultimately produced.

The Mechanism

The 5'-UTR is not silent. It contains secondary structures (hairpin loops, internal ribosome entry elements, and upstream open reading frames) that regulate ribosome access and translation efficiency. A single-nucleotide change in this region can flatten or deepen a hairpin that otherwise impedes ribosomal scanning, raising the rate at which ribosomes reach the main IL-4 coding sequence. The T allele at position +33 is associated with higher IL-4 plasma levels in genotype-stratified studies — an association documented in multiple genotype-stratified studies — T allele carriers consistently show higher in-vivo IL-4 plasma levels than CC homozygotes, a relationship that is amplified when the T allele at this 5’-UTR site co-occurs with the IL4 VNTR allele-1 on the same haplotype (Bibert et al., Immunogenetics 2015²² (Bibert et al., Immunogenetics 2015
doi:10.1007/s00251-015-0836-3). The rs2070874 variant is also in strong linkage disequilibrium with rs2243250, the -589C>T promoter SNP. The two variants co-segregate on the same haplotype — the T alleles at both sites tend to be inherited together, and together they confer higher IL-4 transcription (rs2243250 effect via NFAT-1 binding) plus potentially higher translation efficiency (rs2070874 5'-UTR effect). The combined haplotype represents the most biologically active IL-4 configuration.

The Evidence

The strongest evidence for rs2070874 comes from a 2020 meta-analysis of 24 publications³³ 2020 meta-analysis of 24 publications
Imani et al., BMC Medical Genetics — 28 studies pooling 6,587 asthma cases and 8,408 controls with searches in Web of Science, Scopus, and PubMed. In the overall population, the T allele was a significant risk factor under all genotype models tested. Ethnicity- specific analysis found the association significant in Europeans across all models except heterozygote comparison, and in Americans and Asians across several models. Age-stratified analysis confirmed T allele risk in pediatric, adult, and mixed-age cohorts under the allelic model. An earlier 2014 meta-analysis⁴⁴ 2014 meta-analysis
Zheng et al. independently confirmed the -33C/T polymorphism as an asthma risk factor across ethnically diverse studies.

For atopic dermatitis, a 2016 pediatric case-control study⁵⁵ 2016 pediatric case-control study
Saadat et al., Allergy Asthma Immunol Res found that IL-4 gene polymorphisms including rs2070874 contribute to elevated atopic dermatitis risk in children, with T allele carriers showing higher serum IL-4 levels. The direct IgE link was established in early work by Howard et al. 2001⁶⁶ Howard et al. 2001, who associated the C+33T polymorphism directly with elevated total serum IgE in atopic cohorts.

Beyond classic atopy, a 2022 haplotype analysis⁷⁷ 2022 haplotype analysis
Junta et al., Genes of 195 patients demonstrated that the IL4 haplotype containing the rs2070874 T allele was significantly associated with NSAID-exacerbated respiratory disease (AERD/N-ERD) — the severe aspirin-sensitive asthma phenotype defined by nasal polyps, eosinophilic inflammation, and reactions to COX-1 inhibitors. This finding extends the IL4 5'-UTR variant's clinical footprint from common atopy to the most refractory eosinophilic asthma phenotype.

Evidence level: strong. Meta-analyses replicate across multiple ethnicities, ages, and atopic disease phenotypes; the biology (5'-UTR regulation of translation, plasma IL-4 elevation, serum IgE elevation) is mechanistically coherent.

Practical Actions

For T allele carriers, the elevated IL-4 output means: (1) total serum IgE is a directly informative biomarker — T allele carriers' IgE trends higher, and periodic measurement reveals whether the IL-4 pathway is biologically active; (2) quercetin and related flavonoids suppress IL-4 and IL-13 gene transcription in activated T cells with mechanistic specificity to this pathway; (3) for TT homozygotes with active moderate-to-severe atopic disease, dupilumab (which blocks the IL-4Rα receptor used by both IL-4 and IL-13) is the biologically best-matched therapy; (4) aspirin and NSAIDs warrant caution in T allele carriers with asthma, given the haplotype association with NSAID-exacerbated respiratory disease.

Interactions

rs2070874 is in strong linkage disequilibrium with rs2243250 (IL4 -589C>T) — the two T alleles co-segregate on the same haplotype. Carriers of both T alleles have the highest constitutive IL-4 output from combined promoter-level (NFAT-1 binding enhancement) and 5'-UTR-level (translation efficiency) effects. Haplotype-level analysis consistently shows stronger disease associations for the T/T haplotype at both sites than for either variant alone.

The rs1801275 variant (IL-4Rα Arg576Gln) alters the cytoplasmic signalling domain of the shared IL-4/IL-13 receptor chain. When elevated IL-4 production (rs2070874 T allele) meets altered receptor signal transduction (rs1801275), Th2 pathway output may be doubly amplified — a biologically plausible interaction that is relevant to dupilumab pharmacogenomics.

The rs20541 variant (IL-13 Arg130Gln) elevates IL-13 output through a separate gene but shares the IL-4Rα signalling chain. Carriers of both rs2070874-T and rs20541-A face combined Th2 cytokine over-activity from both arms of the IL-4/IL-13 axis — the combination that dupilumab is designed to block at the receptor level.

This SNP sits in an intron of MTR, the gene encoding methionine synthase — the enzyme that uses vitamin B12 as a cofactor to remethylate homocysteine back to methionine. Unlike the well-known missense variant rs1805087 (MTR A2756G / D919G), rs2275565 does not change the amino acid sequence of the enzyme. Instead, it appears to act as a regulatory variant that modestly shifts MTR expression or splicing and, as a consequence, influences how efficiently the one-carbon cycle runs under B12 and folate stress.

The Mechanism

rs2275565 is a G>T change on the plus strand at chr1:236885376 (GRCh38), located within an MTR intron across multiple transcript variants ¹¹ The variant is annotated as an intron variant by Ensembl VEP and as benign by ClinVar, but observational studies repeatedly link the T allele to higher plasma homocysteine. Because it is intronic it has no direct effect on the methionine synthase protein sequence. The most likely mechanism is a small effect on transcription, splicing, or mRNA stability that reduces enzyme abundance at the margin — enough to matter when B12 or folate supply is limited, but too subtle to show up in well-nourished cohorts.

The Folate/B12 Pathway Context

MTR sits at the convergence of the folate and B12 cycles. It takes a methyl group from 5-methyltetrahydrofolate (produced by MTHFR) and transfers it to homocysteine via a methylcobalamin intermediate. When MTR output drops, two things happen at once: homocysteine builds up, and methylfolate accumulates unusably — the so-called "methyl-folate trap" ²² Methylfolate can only donate its methyl group through MTR; when MTR is slow, methylfolate traps the folate pool in an unusable form. Because rs2275565 is a quantitative tweak rather than a missense hit, its phenotype is most visible when other pressures are in play: low B12 intake, competing MTHFR or MTRR variants, oxidative stress, or pregnancy.

The Evidence

The strongest recent signal comes from a Chinese case-control study³³ Chinese case-control study
Liu et al. Association of MTR gene polymorphisms with non-syndromic congenital heart disease. Scientific Reports, 2023 of 620 infants with non-syndromic congenital heart disease versus 620 controls. The TT genotype was associated with a roughly 5-fold increased risk of CHD (aOR 4.93, 95% CI 1.93–12.58), and the heterozygous GT genotype with a ~1.5-fold increase. This fits the broader pattern in which maternal one-carbon metabolism disturbances raise developmental risk for neural tube and cardiac defects.

Homocysteine findings are more mixed. The NHLBI Family Heart Study⁴⁴ NHLBI Family Heart Study
Jacques et al. Effects of MTR and MTRR polymorphisms on total plasma homocysteine, Atherosclerosis 2003 (n=677) found no significant effect of MTR variants on fasting plasma homocysteine but a trend toward higher post-methionine-load homocysteine in carriers. Overall the evidence level is moderate: the biological direction is consistent (T allele → more stress on the B12/folate cycle), but effect sizes in well-nourished populations are small and not all studies replicate.

Practical Actions

For T allele carriers, the practical move is to keep B12 status unambiguously generous — this is the cofactor MTR can't do without. Methylcobalamin or hydroxocobalamin are preferable to cyanocobalamin because they bypass a reduction step. Pairing with methylfolate (rather than synthetic folic acid) is the standard complement when there are also MTHFR variants present. Periodic homocysteine testing gives an objective readout of whether the cycle is running cleanly.

Interactions

rs2275565 is most meaningful when stacked with other one-carbon variants: rs1805087 (MTR D919G, the missense MTR variant), rs1801394 (MTRR A66G, which handles B12 reactivation), and rs1801133 (MTHFR C677T, the upstream methylfolate producer). A person heterozygous at rs2275565 alone is typically fine; a person with MTHFR TT plus one or both MTR hits benefits from more deliberate B12 and methylfolate support.